Klin Padiatr 2012; 224(04): 233-240
DOI: 10.1055/s-0032-1316296
Review
© Georg Thieme Verlag KG Stuttgart · New York

Regenerative Therapies in Neonatology: Clinical Perspectives

Regenerative Therapien in der Neonatologie: Perspektiven für die Klinik
L. Gortner
1   Pediatric Hospital, University of the Saarland, Homburg, Germany
,
U. Felderhoff-Müser
2   Department, of Pediatrics, University Hospital Essen, Germany
,
D. Monz
1   Pediatric Hospital, University of the Saarland, Homburg, Germany
,
K. Bieback
3   Institute of Transfusion Medicine and Immunology, Medical Faculty Mannheim, Germany
,
H. Klüter
3   Institute of Transfusion Medicine and Immunology, Medical Faculty Mannheim, Germany
,
R. Jellema
4   Department of Pediatric/Neonatology, University Medical Center, Maastricht, The Netherlands
,
B. W. Kramer
4   Department of Pediatric/Neonatology, University Medical Center, Maastricht, The Netherlands
,
M. Keller
1   Pediatric Hospital, University of the Saarland, Homburg, Germany
,
I. Reiss
5   Department of Neonatology, Erasmus MC-Sophia, Rotterdam, The Netherlands
,
P. A. Horn
6   Institute for Transfusion Medicine, University Hospital Essen, Germany
,
B. Giebel
6   Institute for Transfusion Medicine, University Hospital Essen, Germany
› Author Affiliations
Further Information

Publication History

Publication Date:
20 June 2012 (online)

Preview

Abstract

Regenerative therapy based on stem cells is applied as standard therapy in pediatric oncology. Furthermore, they are frequently used to treat immunodeficiency disorders of infants. For severe neonatal diseases, e. g. hypoxic-ischemic encephalopathy in term neonates or bronchopulmonary dysplasia in preterm infants, animal models have been established. According to some first preclinical results stem cell administration appears as a promising tool to improve the clinical outcome in high-risk infants. Provided the benefit of regenerative therapies can further be evaluated in appropriate preclinical neonate models, carefully controlled clinical trials to assess the significance of regenerative therapies, such as autologous stem cell administration, are indicated.

Zusammenfassung

Regenerative Therapien sind Standard bei onkologischen pädiatrischen Erkrankungen sowie Immundefekten, wobei sowohl Stammzellen als auch Wachstumsfaktoren eingesetzt werden. In der Neonatologie wurden bislang nur tierexperimentell bei hypoxisch-ischämischer Enzephalopathie und bei der bronchopulmonalen Dysplasie Stammzellen mit Erfolg appliziert. Diese Ergebnisse legen nahe, dass bei Bestätigung dieser Befunde in weiteren experimentellen Studien kontrollierte Studien an Hochrisikokindern notwendig sind. Der Einsatz von autologen Stammzellpräparaten ist hierbei ein erster Schritt, um die Bedeutung der regenerativen Therapie in der Neonatologie zu evaluieren.